Exposure-Response Relationships for Therapeutic Biologic Products

Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development

Volumn , Issue , 2006, Pages 295-327

  Tabrizi, Mohammad ^a   Roskos, Lorin K ^a  

^a AMGEN INC   (United States)

Author keywords

Biotech drugs; Cytokines; Growth factors; Hormones; Monoclonal antibodies (mAbs); Pharmacodynamics; Pharmacokinetics; Soluble receptors; Therapeutic biologic products

Indexed keywords

EID: 84889815803     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527609628.ch12     Document Type: Chapter

References (117)

1. Galluppi, G.R., M.C. Rogge, L.K. Roskos, L.J. Lesko, M.D. Green, D.W. Feigal, Jr., and C.C. Peck. 2001. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin. Pharmacol. Ther. 69 : 387-399.
2. Tang, L., A.M. Persky, G. Hochhaus, and B. Meibohm. 2004. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 93 : 2184-2204.
3. Toon, S. 1996. The relevance of pharmacokinetics in the development of biotechnology products. Eur. J. Drug Metab. Pharmacokinet. 21: 93-103.
4. Supersaxo, A., W. Hein, H. Gallati, and H. Steffen. 1988. Recombinant human interferon alpha-2 a: delivery to lymphoid tissue by selected modes of application. Pharm. Res. 5 : 472-476.
5. Supersaxo, A., W.R. Hein, and H. Steffen. 1990. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 7: 167-169.
6. Wang, B., T.M. Ludden, E.N. Cheung, G.G. Schwab, and L.K. Roskos. 2001. Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J. Pharmacokinet. Pharmacodyn. 28 : 321-342.
7. Weinstein, J.N. and W. van Osdol. 1992. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int. J. Immunopharmacol. 14 : 457-463.
8. Gerlowski, L.E. and R.K. Jain. 1986. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31: 288-305.
9. Ghetie, V., J.G. Hubbard, J.K. Kim, M.F. Tsen, Y. Lee, and E.S. Ward. 1996. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur. J. Immunol. 26 : 690-696.
10. Roskos, L.K., G.C. Davis, and G.M. Schwab. 2004. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev. Res. 61: 108-120.
11. Tabrizi, M.A., C.-M.L. Tseng, and L.K. Roskos. 2006. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discovery Today 11: 81-88.
12. Cohen-Solal, J.F., L. Cassard, W.H. Fridman, and C. Sautes-Fridman. 2004. Fc gamma receptors. Immunol. Lett. 92 : 199-205.
13. Bogers, W.M., R.K. Stad, D.J. Janssen, N. van Rooijen, L.A. van Es, and M.R. Daha. 1991. Kupffer cell depletion in vivo results in preferential elimination of IgG aggregates and immune complexes via specific Fc receptors on rat liver endothelial cells. Clin. Exp. Immunol. 86 : 328-333.
14. Hinton, P.R., M.G. Johlfs, J.M. Xiong, K. Hanestad, K.C. Ong, C. Bullock, S. Keller, M.T. Tang, J.Y. Tso, M. Vasquez, and N. Tsurushita. 2004. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279 : 6213-6216.
15. Neel, N.F., E. Schutyser, J. Sai, G.H. Fan, and A. Richmond. 2005. Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev. 16 : 637-658.
16. Schellekens, H. 2005. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20 (Suppl. 6):vi3-vi9.
17. Roskos, L.K., S.A. Kellermann, and K.A. Foon. 2005. Human Antiglobulin Responses. In: M.T. Lotze and A.W. Thomson (Eds.), Measuring Immunity: Basic Science and Clinical Practice. Elsevier Academic Press, London, pp. 172-186.
18. Johansson, A., A. Erlandsson, D. Eriksson, A. Ullen, P. Holm, B.E. Sundstrom, K.H. Roux, and T. Stigbrand. 2002. Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer 94 : 1306-1313.
19. Kharagjitsingh, A.V., J.C. Korevaar, J.P. Vandenbroucke, E.W. Boeschoten, R.T. Krediet, M.R. Daha, F.W. Dekker. 2005. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int. 68 : 1215-1222.
20. Li, J., C. Yang, Y. Xia, A. Bertino, J. Glaspy, M. Roberts, and D.J. Kuter. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98 : 3241-3248.
21. Holford, N.H. and L.B. Sheiner. 1981. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6 : 429-453.
22. Holford, N.H. and L.B. Sheiner. 1981. Pharmacokinetic and pharmacodynamic modeling in vivo. Crit. Rev. Bioeng. 5 : 273-322.
23. Holford, N.H. 1991. Relevance of pharmacodynamic principles in therapeutics. Ann. Acad. Med. Singapore 20 : 26-30.
24. Sheiner, L.B. and J.L. Steimer. 2000. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol. 40 : 67-95.
25. Mager, D.E., E. Wyska, and W.J. Jusko. 2003. Diversity of mechanism-based pharmacodynamic models. Drug Metab. Dispos. 31: 510-518.
26. Mager, D.E. and W.J. Jusko. 2001. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28 : 507-532.
27. Mager, D.E. and W.J. Jusko. 2001. Pharmacodynamic modeling of time-dependent transduction systems. Clin. Pharmacol. Ther. 70 : 210-216.
28. Sharma, A. and W.J. Jusko. 1998. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br. J. Clin. Pharmacol. 45 : 229-239.
29. Sun, Y.N. and W.J. Jusko. 1998. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J. Pharm. Sci. 87 : 732-737.
30. Tabrizi-Fard, M.A. and H.L. Fung. 1998. Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. Pharm. Res. 15 :1063-1068.
31. Dall'Acqua, W.F., R.M. Woods, E.S. Ward, S.R. Palaszynski, N.K. Patel, Y.A. Brewah, H. Wu, P.A. Kiener, and S. Langermann. 2002. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol. 169 : 5171-5180.
32. Raghavan, M., V.R. Bonagura, S.L. Morrison, and P.J. Bjorkman. 1995. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 34 :14649-14657.
33. Shields, R.L., A.K. Namenuk, K. Hong, Y.G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, J.A. Fox, and L.G. Presta. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn. and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276 : 6591-6604.
34. Presta, L.G., R.L. Shields, A.K. Namenuk, K. Hong, and Y.G. Meng. 2002. Engineering therapeutic antibodies for improved function. Biochem. Soc. Trans. 30: 487-490.
35. Idusogie, E.E., P.Y. Wong, L.G. Presta, H. Gazzano-Santoro, K. Totpal, M. Ultsch, and M.G. Mulkerrin. 2001. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166 : 2571-2575.
36. Ward, E.S. and V. Ghetie. 1995. The effector functions of immunoglobulins: implications for therapy. Ther. Immunol. 2 : 77-94.
37. Abbas, A.K. and C.A. Janeway, Jr. 2000. Immunology: improving on nature in the twenty-first century. Cell 100 :129-138.
38. Pfeifer, M.A., R.J. Graf, J.B. Halter, and D. Porte, Jr. 1981. The regulation of glucose-induced insulin secretion by pre-stimulus glucose level and tolbutamide in normal man. Diabetologia 21: 198-205.
39. Roach, P. and J.R. Woodworth. 2002. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin. Pharmacokinet. 41: 1043-1057.
40. Brange, J., D.R. Owens, S. Kang, and A. Volund. 1990. Monomeric insulins and their experimental and clinical implications. Diabetes Care 13 : 923-954.
41. Vignati, L., J.H. Anderson, Jr., and P.W. Iversen. 1997. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulindependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clin. Ther. 19: 1408-1421.
42. DeFronzo, R.A., J.D. Tobin, and R. Andres. 1979. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237:E214-E223.
43. Osterberg, O., L. Erichsen, S.H. Ingwersen, A. Plum, H.E. Poulsen, and P. Vicini. 2003. Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. J. Pharmacokinet. Pharmacodyn. 30 : 221-235.
44. Chorev, M. 2002. Parathyroid hormone 1 receptor: insights into structure and function. Receptors Channels 8 : 219-242.
45. Fukugawa, M. and K. Kurokawa. 2002. Calcium homeostasis and imbalance. Nephron 92 (Suppl. 1):41-45.
46. Berg, C., K. Neumeyer, and P. Kirkpatrick. 2003. Teriparatide. Nat. Rev. Drug Discov. 2 : 257-258.
47. Deal, C. 2004. The use of intermittent human parathyroid hormone as a treatment for osteoporosis. Curr. Rheumatol. Rep. 6 : 49-58.
48. Dobnig, H., A. Sipos, Y. Jiang, A. Fahrleitner-Pammer, L.G. Ste-Marie, J.C. Gallagher, I. Pavo, J. Wang, and E.F. Eriksen. 2005. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J. Clin. Endocrinol. Metab. 90 : 3970-3977.
49. Frolik, C.A., E.C. Black, R.L. Cain, J.H. Satterwhite, P.L. Brown-Augsburger, M. Sato, and J.M. Hock. 2003. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33 : 372-379.
50. Onyia, J.E., L.M. Helvering, L. Gelbert, T. Wei, S. Huang, P. Chen, E.R. Dow, A. Maran, M. Zhang, S. Lotinun, X. Lin, D.L. Halladay, R.R. Miles, N.H. Kulkarni, E.M. Ambrose, Y.L. Ma, C.A. Frolik, M. Sato, H.U. Bryant, and R.T. Turner. 2005. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J. Cell Biochem. 95 : 403-418.
51. Chauvin, S., M. Bencsik, T. Bambino, and R.A. Nissenson. 2002. Parathyroid hormone receptor recycling: role of receptor dephosphorylation and betaarrestin. Mol. Endocrinol. 16 : 2720-2732.
52. Potter, L.K., L.D. Greller, C.R. Cho, M.E. Nuttall, G.B. Stroup, L.J. Suva, and F.L. Tobin. 2005. Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics. Bone 37 : 159-169.
53. McDermott, D.F. and M.B. Atkins. 2004. Application of IL-2 and other cytokines in renal cancer. Expert Opin. Biol. Ther. 4 : 455-468.
54. Rosenberg, S.A., J.C. Yang, S.L. Topalian, D.J. Schwartzentruber, J.S. Weber, D.R. Parkinson, C.A. Seipp, J.H. Einhorn, and D.E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907-913.
55. Yang, J.C., R.M. Sherry, S.M. Steinberg, S.L. Topalian, D.J. Schwartzentruber, P. Hwu, C.A. Seipp, L. Rogers-Freezer, K.E. Morton, D.E. White, D.J. Liewehr, M.J. Merino, and S.A. Rosenberg. 2003. Randomized study of high-dose and lowdose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21: 3127-3132.
56. McDermott, D.F., M.M. Regan, J.I. Clark, L.E. Flaherty, G.R. Weiss, T.F. Logan, J.M. Kirkwood, M.S. Gordon, J.A. Sosman, M.S. Ernstoff, C.P. Tretter, W.J. Urba, J.W. Smith, K.A. Margolin, J.W. Mier, J.A. Gollob, J.P. Dutcher, and M.B. Atkins. 2005. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23 :133-141.
57. Harker, L.A., L.K. Roskos, U.M. Marzec, R.A. Carter, J.K. Cherry, B. Sundell, E.N. Cheung, D. Terry, and W. Sheridan. 2000. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95 : 2514-2522.
58. Uehlinger, D.E., F.A. Gotch, and L.B. Sheiner. 1992. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin. Pharmacol. Ther. 51: 76-89.
59. Krzyzanski, W., W.J. Jusko, M.C.Wacholtz, N. Minton, and W.K. Cheung. 2005. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur. J. Pharm. Sci. 26 : 295-306.
60. Ramakrishnan, R., W.K. Cheung, M.C. Wacholtz, N. Minton, and W.J. Jusko. 2004. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J. Clin. Pharmacol. 44 : 991-1002.
61. Jumbe, N., B. Yao, R. Rovetti, G. Rossi, and A.C. Heatherington. 2002. Clinical trial simulation of a 200-microg fixed dose of darbepoetin-′ in chemotherapyinduced anemia. Oncology (Williston. Park) 16 : 37-44.
62. Immunex Corp. 2005. Enbrel prescribing information.
63. Lee, H., H.C. Kimko, M. Rogge, D.Wang, I. Nestorov, and C.C. Peck. 2003. Population pharmacokinetic and pharmacody namic modeling of etanercept using logistic regression analysis. Clin. Pharmacol. Ther. 73 : 348-365.
64. Leonardi, C.L., J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, A. Wang, and A.B. Gottlieb. 2003. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349 : 2014-2022.
65. Bathon, J.M., R.W. Martin, R.M. Fleischmann, J.R. Tesser, M.H. Schiff, E.C. Keystone, M.C. Genovese, M.C. Wasko, L.W. Moreland, A.L. Weaver, J. Markenson, and B.K. Finck. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343 : 1586-1593.
66. Abbas, A.K. 1982. Immunoglobulin idiotypes; experimental and clinical applications. Indian J. Pediatr. 49 : 641-648.
67. Abbas, A.K. 1989. Antigen presentation by B lymphocytes: mechanisms and functional significance. Semin. Immunol. 1: 5-12.
68. Huse, W.D., L. Sastry, S.A. Iverson, A.S. Kang, M. Alting-Mees, D.R. Burton, S.J. Benkovic, and R.A. Lerner. 1989. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246 : 1275-1281.
69. McCafferty, J., A.D. Griffiths, G. Winter, and D.J. Chiswell. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348 : 552-554.
70. Mendez, M.J., L.L. Green, J.R. Corvalan, X.C. Jia, C.E. Maynard-Currie, X.D. Yang, M.L. Gallo, D.M. Louie, D.V. Lee, K.L. Erickson, J. Luna, C.M. Roy, H. Abderrahim, F. Kirschenbaum, M. Noguchi, D.H. Smith, A. Fukushima, J.F. Hales, S. Klapholz, M.H. Finer, C.G. Davis, K.M. Zsebo, and A. Jakobovits. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15 : 146-156.
71. Anderson, P.J. 2005. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin. Arthritis Rheum. 34 : 19-22.
72. Nahar, I.K., K. Shojania, C.A. Marra, A.H. Alamgir, and A.H. Anis. 2003. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann. Pharmacother. 37 : 1256-1265.
73. Genentech Inc. 2005. Raptiva prescribing information.
74. Genentech Inc. 2005. Xolair prescribing information.
75. Chapman, T.M. and G.M. Keating. 2003. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 63 : 2803-2835.
76. Wiland, A.M. and B. Philosophe. 2004. Daclizumab induction in solid organ transplantation. Expert Opin. Biol. Ther. 4 : 729-740.
77. Feldmann, M. and R.N. Maini. 2003. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other auto immune diseases. Nat. Med. 9: 1245-1250.
78. den Broeder, A., L. van de Putte, R. Rau, M. Schattenkirchner, P. Van Riel, O. Sander, C. Binder, H. Fenner, Y. Bankmann, R. Velagapudi, J. Kempeni, and H. Kupper. 2002. A single dose, placebo controlled study of the fully human antitumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol. 29 : 2288-2298.
79. St Clair, E.W., C.L. Wagner, A.A. Fasanmade, B. Wang, T. Schaible, A. Kavanaugh, and E.C. Keystone. 2002. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46 : 1451-1459.
80. Baert, F., M. Noman, S. Vermeire, G. Van Assche, G. D'Haens, A. Carbonez, and P. Rutgeerts. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348 : 601-608.
81. Bauer, R.J., R.L. Dedrick, M.L. White, M.J. Murray, and M.R. Garovoy. 1999. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J. Pharmacokinet. Biopharm. 27 : 397-420.
82. Mortensen, D.L., P.A. Walicke, X. Wang, P. Kwon, P. Kuebler, A.B. Gottlieb, J.G. Krueger, C. Leonardi, B. Miller, and A. Joshi. 2005. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J. Clin. Pharmacol. 45 : 286-298.
83. Sun, Y.N., J.F. Lu, A. Joshi, P. Compton, P. Kwon, and R.A. Bruno. 2005. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J. Clin. Pharmacol. 45 : 468-476.
84. Coffey, G.P., E. Stefanich, S. Palmieri, R. Eckert, J. Padilla-Eagar, P.J. Fielder, and S. Pippig. 2004. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J. Pharmacol. Exp. Ther. 310 : 896-904.
85. Coffey, G.P., J.A. Fox, S. Pippig, S. Palmieri, B. Reitz, M. Gonzales, A. Bakshi, J. Padilla-Eagar, and P.J. Fielder. 2005. Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab. Dispos. 33 : 623-629.
86. Babu, K.S., S.H. Arshad, and S.T. Holgate. 2001. Anti-IgE treatment: an update. Allergy 56 : 1121-1128.
87. Milgrom, H., R.B. Fick, Jr., J.Q. Su, J.D. Reimann, R.K. Bush, M.L. Watrous, and W.J. Metzger. 1999. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N. Engl. J. Med. 341: 1966-1973.
88. Easthope, S. and B. Jarvis. 2001. Omalizumab. Drugs 61: 253-260.
89. Ruffin, C.G. and B.E. Busch. 2004. Omalizumab: a recombinant humanized anti-IgE antibody for allergic asthma. Am. J. Health Syst. Pharm. 61: 1449-1459.
90. Biogen Idec Inc. and Genentech Inc. 2005. Rituxan prescribing information.
91. Genzyme Inc. 2005. Campath prescribing information.
92. Genentech Inc. 2005. 2.
93. Imclone Systems Inc. and Bristol-Myers Squibb Corp. 2004. Erbitux prescribing information.
94. Genentech Inc. 2005. 2.
95. McKeage, K. and C.M. Perry. 2002. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62 : 209-243.
96. Smith, M.R. 2003. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22 : 7359-7368.
97. Dall'Ozzo, S., S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault. 2004. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64 : 4664-4669.
98. Mangel, J., R. Buckstein, K. Imrie, D. Spaner, E. Franssen, P. Pavlin, A. Boudreau, N. Pennell, D. Combs, and N.L. Berinstein. 2003. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Ann. Oncol. 14 : 758-765.
99. Reff, M.E., K. Carner, K.S. Chambers, P.C. Chinn, J.E. Leonard, R. Raab, R.A. Newman, N. Hanna, and D.R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 : 435-445.
100. Schroder, C., A.M. Azimzadeh, G. Wu, J.O. Price, J.B. Atkinson, and R.N. Pierson. 2003. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl. Immunol. 12 : 19-28.
101. Keating, M. and S. O'Brien. 2000. Highdose rituximab therapy in chronic lymphocytic leukemia. Semin. Oncol. 27 : 86-90.
102. O'Brien, S.M., H. Kantarjian, D.A.Thomas, F.J. Giles, E.J. Freireich, J. Cortes, S. Lerner, and M.J. Keating. 2001. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19 : 2165-2170.
103. Manshouri, T., K.A. Do, X. Wang, F.J. Giles, S.M. O'Brien, H. Saffer, D. Thomas, I. Jilani, H.M. Kantarjian, M.J. Keating, and M. Albitar. 2003. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101: 2507-2513.
104. Verheul, H.M. and H.M. Pinedo. 2005. Inhibition of angiogenesis in cancer patients. Expert Opin. Emerg. Drugs 10 : 403-412.
105. Rini, B.I. and E.J. Small. 2005. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 23 : 1028-1043.
106. Motl, S. 2005. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am. J. Health Syst. Pharm. 62 : 1021-1032.
107. Gerber, H.P. and N. Ferrara. 2005. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65 : 671-680.
108. Willett, C.G., Y. Boucher, E. di Tomaso, D.G. Duda, L.L. Munn, R.T. Tong, D.C. Chung, D.V. Sahani, S.P. Kalva, S.V. Kozin, M. Mino, K.S. Cohen, D.T. Scadden, A.C. Hartford, A.J. Fischman, J.W. Clark, D.P. Ryan, A.X. Zhu, L.S. Blaszkowsky, H.X. Chen, P.C. Shellito, G.Y. Lauwers, and R.K. Jain. 2004. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10 : 145-147.
109. Aggarwal, S. and E. Chu. 2005. Current therapies for advanced colorectal cancer. Oncology (Williston. Park) 19 : 589-595.
110. Gordon, M.S., K. Margolin, M. Talpaz, G.W. Sledge, Jr., E. Holmgren, R. Benjamin, S. Stalter, S. Shak, and D. Adelman. 2001. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19 : 843-850.
111. Margolin, K., M.S. Gordon, E. Holmgren, J. Gaudreault, W. Novotny, G. Fyfe, D. Adelman, S. Stalter, and J. Breed. 2001. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 19 : 851-856.
112. Herbst, R.S., D.H. Johnson, E. Mininberg, D.P. Carbone, T. Henderson, E.S. Kim, G. Blumenschein, Jr., J.J. Lee, D.D. Liu, M.T. Truong, W.K. Hong, H. Tran, A. Tsao, D. Xie, D.A. Ramies, R. Mass, S. Seshagiri, D.A. Eberhard, S.K. Kelley, and A. Sandler. 2005. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23 : 2544-2555.
113. Harari, P.M. 2004. Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer 11: 689-708.
114. Bruno, R., C.B. Washington, J.F. Lu, G. Lieberman, L. Banken, and P. Klein. 2005. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother. Pharmacol. 56 : 361-369.
115. Pegram, M.D., A. Lipton, D.F. Hayes, B.L. Weber, J.M. Baselga, D. Tripathy, D. Baly, S.A. Baughman, T. Twaddell, J.A. Glaspy, and D.J. Slamon. 1998. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16 : 2659-2671.
116. Leyland-Jones, B., K. Gelmon, J.P. Ayoub, A. Arnold, S. Verma, R. Dias, and P. Ghahramani. 2003. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J. Clin. Oncol. 21: 3965-3971.
117. Tokuda, Y., T. Watanabe, Y. Omuro, M. Ando, N. Katsumata, A. Okumura, M. Ohta, H. Fujii, Y. Sasaki, T. Niwa, and T. Tajima. 1999. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br. J. Cancer 81: 1419-1425.